65,437 trials
Healthy · Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Pirtobrutinib — 4240; 4410; 4140; 3270 nanogram per milliliter (ng/mL)
Stimulant Use
Primary: Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 19.2; 57.8…
Dementia · Caregiver Burden · Relation, Family
Primary: Resourcefulness — 9.20 score on a scale
Low Back Pain
Primary: Time to First Achieve a Numeric Rating Scale-Pain Intensity Score <4 or a Pain Intensity Reduction of ≥30% From Drug Intake Till 8 Hours After the First Dose — 105; 120…
Parkinson Disease · Parkinson Disease Dementia
Primary: Velocity — .977; .960; 1.042; 1.011 meters per second
Upper Extremity Weakness · Stroke
Primary: Wearing Tolerance of the SCD and Sleeve on the Upper Extremity. — 20 Participants
Duchenne Muscular Dystrophy · Cardiomyopathy
Primary: Number of Participants Experiencing Any of the Adjudicated Events — 0; 0; 0; 0 Participants
Contrast-induced Acute Kidney Injury
Primary: Number of Patients With Acute Kidney Injury — 8; 16 Participants
Duchenne Muscular Dystrophy
Primary: Change in FVC (%-Predicted) From Baseline to 2 Years. — -9.2; -6.4 Mean difference in FVC %-predicted — p=0.68
Gastric Cancer
Primary: Propofol EC50 for Inducing Loss of Conciousness — 2.97; 3.36 ug/ml
Knee Osteoarthritis
Primary: WOMAC Pain Change — 1; .7571 WOMAC pain score
Exercise
Primary: Pain Pressure Threshold — 0.72; 1.13 kg/cm^2
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 12 — 5.63; 5.30 %Change of BMD
Hypertrophic Cardiomyopathy
Primary: Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events — 13; 5 Participants
MEDICATION RELATED OSTEONECROSIS OF THE JAW
Primary: Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Inflammatory Phase — 2; 2.49 score on a scale